$9.18
3.16% yesterday
Nasdaq, Nov 18, 10:00 pm CET
ISIN
US52886X1072
Symbol
LXEO

Lexeo Therapeutics Stock price

$9.18
-0.04 0.43% 1M
+5.89 179.03% 6M
+2.60 39.51% YTD
+3.18 53.00% 1Y
-1.82 16.55% 3Y
-1.82 16.55% 5Y
-1.82 16.55% 10Y
-1.82 16.55% 20Y
Nasdaq, Closing price Tue, Nov 18 2025
-0.30 3.16%
ISIN
US52886X1072
Symbol
LXEO
Industry

Key metrics

Basic
Market capitalization
$691.9m
Enterprise Value
$570.2m
Net debt
positive
Cash
$122.8m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.7
Financial Health
Equity Ratio
79.5%
Return on Equity
-83.9%
ROCE
-89.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-112.6m | $-104.0m
EBIT
$-113.5m | $-118.3m
Net Income
$-105.0m | $-140.6m
Free Cash Flow
$-107.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-22.5% | 1.3%
EBIT
-21.4% | -11.6%
Net Income
-21.1% | -43.5%
Free Cash Flow
-59.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-2.0
Short interest
7.7%
Employees
61
Rev per Employee
$0.0
Show more

Is Lexeo Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Lexeo Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Lexeo Therapeutics forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Lexeo Therapeutics forecast:

Buy
93%
Hold
7%

Financial data from Lexeo Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 48 48
62% 62%
-
- Research and Development Expense 66 66
3% 3%
-
-113 -113
23% 23%
-
- Depreciation and Amortization 0.96 0.96
41% 41%
-
EBIT (Operating Income) EBIT -114 -114
21% 21%
-
Net Profit -105 -105
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Lexeo Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexeo Therapeutics Stock News

Positive
Seeking Alpha
12 days ago
Lexeo Therapeutics, Inc. has surged after FDA alignment on a pivotal trial for LX2006, targeting Friedreich's ataxia cardiomyopathy. LX2006 shows promising efficacy and safety, with significant LVMI reduction and increased frataxin expression, positioning LXEO as a potential best-in-class therapy. LXEO is well-funded into 2028 after recent financings, and analysts remain bullish, forecasting st...
Neutral
GlobeNewsWire
14 days ago
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal st...
Neutral
GlobeNewsWire
29 days ago
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, befo...
More Lexeo Therapeutics News

Company Profile

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Head office United States
CEO R. Townsend
Employees 61
Founded 2017
Website www.lexeotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today